Product Information
KETAMINE 500 MG/5 ML VIAL is a generic product labeled by Fresenius Kabi USA, LLC, priced at $1.7804 per ML under NDC 65219018605. Its NADAC has been published 46 times since Nov 19, 2025.
FDA first approved this application on Jan 13, 2023. Its Orange Book therapeutic-equivalence code is AP.
Strength
100 mg/mL
Manufacturer
Fresenius Kabi USA, LLCNDC
65219018605
Classification
Generic
Dosage Form
INJECTION
Route
INTRAMUSCULAR; INTRAVENOUS
Effective Date
9/23/2026
Active Ingredients
KETAMINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA215808FDA Approved
1/13/2023
TE Code
AP
On Market Since
7/10/2023
Pharmacological Classes
Price Statistics
The NADAC for KETAMINE 500 MG/5 ML VIAL has been published 46 times since Nov 19, 2025, and over the history we have for it it has risen 13.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.7804 per ML |
|---|---|
| All-time high | $1.7804 (Sep 30, 2026) |
| All-time low | $1.5436 (Jul 22, 2026) |
| 52-week high | $1.7804 |
| 52-week low | $1.5436 |
| Median price | $1.5599 |
| Average price | $1.5664 |
| Largest weekly change | +15.3% (Sep 23, 2026) |
| Weeks tracked | 46 |
| Tracking since | Nov 19, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the ketamine hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Fresenius Kabi USA, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ketamine hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
General Anesthetic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of KETAMINE 500 MG/5 ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for KETAMINE 500 MG/5 ML VIAL, manufactured by Fresenius Kabi USA, LLC, is $1.7804 per ML (NDC 65219018605), effective Sep 30, 2026.
How has the price of KETAMINE 500 MG/5 ML VIAL changed over time?
Over the history we have for it, the NADAC for KETAMINE 500 MG/5 ML VIAL has risen 13.9%. It has been tracked across 46 weekly CMS publications since Nov 19, 2025.
What are the highest and lowest recorded NADAC prices for KETAMINE 500 MG/5 ML VIAL?
Since Nov 19, 2025, the NADAC for KETAMINE 500 MG/5 ML VIAL has ranged from a low of $1.5436 (Jul 22, 2026) to a high of $1.7804 (Sep 30, 2026), with a median of $1.5599 per ML.
Are there cheaper alternatives to KETAMINE 500 MG/5 ML VIAL?
No other NADAC-published product currently shares the active ingredient and strength of KETAMINE 500 MG/5 ML VIAL in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures KETAMINE 500 MG/5 ML VIAL?
KETAMINE 500 MG/5 ML VIAL (NDC 65219018605) is labeled by Fresenius Kabi USA, LLC, and CMS classifies it as a generic product.